Loading cancer entity…
Subtype
CI-CAN-00002836HNSCC · SCCHNExplore in graph →
Clinical trials
1,589 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (247)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06788990 | FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC(FORTIFI-HN01) | recruiting | Phase 2 / Phase 3 | 650 | Bicara TherapeuticsINDUSTRY | 26 | Jul 17, 2026 | clinicaltrials |
| NCT07398664 | H101 Plus TACE for r/m HNSCC | recruiting | Phase 2 | 20 | West China HospitalOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07665190 | Neoadjuvant EGFR-ADC Combined With Anti-PD-1 Monoclonal Antibody in Resectable Locally Advanced Hypopharyngeal Squamous Cell Carcinoma(RESERVE-HC) | recruiting | Phase 2 | 52 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07586124 | Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma | recruiting | Phase 2 | 80 | Lepu Biopharma Co., Ltd.INDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07601737 | Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma | recruiting | Phase 2 | 182 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT06797986 | A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects With HPV Positive HNSCC. | recruiting | Phase 1 / Phase 2 | 37 | Cellid Co., Ltd.INDUSTRY | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07149207 | Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors | recruiting | Phase 2 | 30 | Medical University of South CarolinaOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07136545 | A Phase I/II Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SirH&N Trial) | recruiting | Phase 1 / Phase 2 | 50 | Taipei Veterans General Hospital, TaiwanOTHER_GOV | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07213934 | Phase I/ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell Carcinoma | recruiting | Phase 1 / Phase 2 | 40 | University of CincinnatiOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06747585 | A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors | recruiting | Phase 1 / Phase 2 | 170 | Alentis Therapeutics AGINDUSTRY | 8 | Jun 29, 2026 | clinicaltrials |
| NCT07094685 | Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer(SENIOR-HN) | recruiting | Phase 2 | 28 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT04114136 | Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies | recruiting | Phase 2 | 72 | Dan ZandbergOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT05726370 | Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC | recruiting | Phase 2 | 28 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07088211 | Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC | recruiting | Phase 2 | 39 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07090317 | Iparomlimab and Tuvonralimab in HNSCC | recruiting | Phase 2 | 30 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT05639972 | E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers | recruiting | Phase 1 / Phase 2 | 15 | Christian HinrichsOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05686226 | E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers | recruiting | Phase 2 | 20 | Christian HinrichsOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05317000 | 5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC | recruiting | Phase 2 | 50 | Barbara BurtnessOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06856213 | Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.(ERBIOTAX) | recruiting | Phase 2 | 65 | Grupo Español de Tratamiento de Tumores de Cabeza y CuelloOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06485778 | A Study of Radiation Therapy After Surgery in People With Oral Tongue Squamous Cell Carcinoma | recruiting | Phase 2 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT05910827 | A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers | recruiting | Phase 1 / Phase 2 | 398 | Hummingbird BioscienceINDUSTRY | 5 | May 27, 2026 | clinicaltrials |
| NCT06648096 | Afatinib in Patients With Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)(AFAN) | recruiting | Phase 1 / Phase 2 | 25 | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauOTHER | 2 | May 27, 2026 | clinicaltrials |
| NCT07497607 | Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma(REDUCE-30) | recruiting | Phase 2 | 31 | Sara MedekOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT07492914 | Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma | recruiting | Phase 2 | 30 | West China HospitalOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT05420948 | A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer | recruiting | Phase 2 | 30 | University of ChicagoOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT05541016 | De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA | recruiting | Phase 2 | 455 | Mayo ClinicOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT06380816 | A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer | recruiting | Phase 1 / Phase 2 | 167 | Cancer Research UKOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07573956 | Trial Evaluating Hypo-fractionated Accelerated Versus Conventional Fractionated Adjuvant RT in Head & Neck Malignancies(Radiotherapy) | recruiting | Phase 2 / Phase 3 | 369 | All India Institute of Medical SciencesOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT06794372 | [68Ga]Ga-FAPI-46 in Staging of Head and Neck Carcinomas(FAPIHN) | recruiting | Phase 2 | 20 | John O. PriorOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07408063 | A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)(BeeHive) | recruiting | Phase 2 | 30 | University Health Network, TorontoOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07419464 | 5-Fluorouracil Response and Optimization STudy (The FROST Trial) | recruiting | Phase 2 | 46 | Washington University School of MedicineOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT05268614 | Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma | recruiting | Phase 2 | 250 | University of FloridaOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT05893888 | A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers | recruiting | Phase 2 / Phase 3 | 40 | Privo TechnologiesINDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07209189 | Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)((NeoScorch HN)) | recruiting | Phase 2 | 75 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05576974 | A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY) | recruiting | Phase 2 | 120 | University of Texas Southwestern Medical CenterOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT05307939 | A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC) | recruiting | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06097468 | Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC) | recruiting | Phase 1 / Phase 2 | 40 | University of California, San FranciscoOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07423078 | Window of Opportunity in Preserving Laryngeal Function Trial(WOLF) | recruiting | Phase 2 | 87 | Matthew SpectorOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06959108 | Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and Neck(IDEAL) | recruiting | Phase 2 | 106 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07189871 | 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors(BetaBart) | recruiting | Phase 1 / Phase 2 | 61 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07465276 | Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC | recruiting | Phase 2 | 32 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06323460 | Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer | recruiting | Phase 2 | 45 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT07485296 | Effect of Postbiotics on Microbiota and Systemic Immunomodulation of Pembrolizumab as First-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC)(POST-BIO) | recruiting | Phase 2 | 45 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT06030440 | De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck(DIREKHT2) | recruiting | Phase 2 / Phase 3 | 508 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07035249 | DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 9 | West China HospitalOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07044635 | Shortened Course of Radiation Therapy After Trans-oral Robotic Surgery in Patients With HPV-Mediated Oropharyngeal Squamous Cell Carcinoma.(RAD RAPTORS) | recruiting | Phase 2 | 42 | University of UtahOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07063212 | A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC) | recruiting | Phase 2 | 40 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT07030257 | Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 150 | Tasca TherapeuticsINDUSTRY | 1 | Feb 18, 2026 | clinicaltrials |
| NCT06636734 | Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial | recruiting | Phase 2 | 28 | Emory UniversityOTHER | 1 | Feb 11, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jul 17, 2026source: clinicaltrials